σ1 Receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain

Neurochemical Research

Volumn 22, Issue 9, 1997, Pages 1105-1109

  Kobayashi, Tetsuya ^a   Matsuno, Kiyoshi ^a   Murai, Masaaki ^a   Mita, Shiro ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

1 receptor agonist; Dopamine synthesis; Dopamine transmission; Frontal cortex; SA4503

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; 1,3 BIS(2 METHYLPHENYL)GUANIDINE; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 3 HYDROXYBENZYLHYDRAZINE; 3,4 DIHYDROXYPHENYLACETIC ACID; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; LEVODOPA; N ALLYLNORMETAZOCINE; OPIATE AGONIST; OPIATE ANTAGONIST; PENTAZOCINE; RECEPTOR SUBTYPE; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; FACILITATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; DOPAMINE; FRONTAL LOBE; MALE; NEURONS; PIPERAZINES; RATS; RATS, WISTAR; RECEPTORS, SIGMA; SYNAPTIC TRANSMISSION;

ANIMALIA;

EID: 0030739636     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1027361101419     Document Type: Article

References (18)

1. Matsuno, K., Matsunaga, K. H., and Mita, S. 1995. Acute effects of σ ligands on the extracellular DOPAC level in rat frontal cortex and striatum, Neurochem. Res. 20:233-238.
2. Hellewell, S. B., and Bowen, B. D. 1990. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain, Brain Res. 527:244-253.
3. Quirion, R., Bowen, W. D., Itzhak, Y., Junien, J. L., Musacchio, J. M., Rothman, R. B., Su, T.-P., Tam, S. W., and Taylor, P. 1992. A proposal for the classification of sigma binding sites, Trends Pharmacol. Sci. 13:85-86.
4. McCann, D. J., Weissman, A. D., and Su, T.-P. 1994. Sigma-1 and sigma-2 sites in rat brain: Comparison of regional, ontogenetic, and subcellular patterns, Synapse 17:182-189.
5. 3H]-1-[1-(2-thienyl)cyclohexyl]piperidine, J. Pharmacol. Exp. Ther. 238:739-748.
6. 3H]SKF10,047 binding in rat and mouse brain: further evidence for phencyclidine/"sigma opiate" receptor commonality, J. Pharmacol. Exp. Ther. 237:681-688.
7. Iyenger, S., Dilworth, V. M., Mick, S. J., Contreras, P. C., Monahan, J. B., Rao, T. S., and Wood, P. L. 1990. Sigma receptors modulate both A9 and A10 dopatninergic neurons in the rat brain: functional interaction with NMDA receptors, Brain Res. 524: 322-326.
8. Quirion, R., Chicheportiche, R., Contreras, P. C., Johnson, K. M., Lodge, D., Tam, S. W., Woods, J. H., and Zukin, S. R. 1987. Classification and nomenclature of phencyclidine and sigma receptor sites, Trends Pharmacol. Sci. 10:444-446.
9. Itzhak, Y. 1994. Multiple sigma binding sites in the brain. Pages 113-137, in Itzhak, Y. (ed.), Sigma Receptors, Academic Press Inc., San Diego.
10. 1 receptor agonist, Eur. J. Pharmacol. 306:271-279.
11. 1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats, Eur. J. Pharmacol. 315:1-10.
12. 1 receptor agonist, in rat brain, J. Pharmacol. Exp. Ther. 279:106-113.
13. 1 receptor agonistic properties, Behav. Brain. Res. 83:221-224.
14. 1 binding sites in guinea pig brain, Eur. J. Pharmacol. 251:R1-R2.
15. Okuyama, S., Imagawa, Y., Ogawa, S., Araki, H., Ajima, A., Tanaka, M., Muramatsu, M., Nakazato, A., Yamaguchi, K., Yoshida, M., and Otomo, S. 1993. NE-100, a novel sigma receptor ligand: in vivo tests, Life Sci. 53:PL285-290.
16. 3H]DOPA in various regions of the brain, J. Neurochem. 13:655-669.
17. Freeman, A. S., and Bunney, B. S. 1984. The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity, Eur. J. Pharmacol. 104:287-293.
18. 10 mesolimbic system by the σ-receptor agonist ( + )SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic, Eur. J. Pharmacol. 154:53-57.